Citi lowered the firm’s price target on Caribou Biosciences (CRBU) to $6 from $30 and keeps a Buy rating on the shares. The firm updated models in the Smid-cap biotech space following the Q3 reports. Citi adjusted its launch timelines for Caribou ‘s three cell therapies in development, saying its prior timelines were too aggressive.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRBU: